2-acetoxy-benzoic acid ; lithium-salt | 552-98-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-acetoxy-benzoic acid ; lithium-salt
• 英文别名: 2-Acetoxy-benzoesaeure; Lithium-Salz；2-Acetoxy-benzoesaeure; Lithium-Verbindung；lithium O-acetylsalicylate；Lithium acetylsalicylate；lithium;2-acetyloxybenzoate
• CAS: 552-98-7
• 化学式: C₉H₇O₄*Li
• 分子量: 186.093
• InChiKey: FGLLQDSAOUJRST-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -3.02
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2918229000

制备方法与用途

阿司匹林（乙酰水杨酸）锂是一种口服活性、有效且不可逆的环氧合酶COX-1和COX-2抑制剂，其IC50值分别为5 μg/mL 和210 μg/mL。这种药物能够诱导细胞凋亡，并能抑制NF-κB的激活。阿司匹林锂还能抑制血小板前列腺素合成酶，预防冠状动脉和脑血管血栓形成。[1][2][3][4][5][6]

反应信息

• 作为产物：
  描述：

  阿司匹林 生成 2-acetoxy-benzoic acid ; lithium-salt
  参考文献：
  名称：

  ABRAMOVICH, A. E.;DMITRIEVA, T. N.;ZHIVITSKAYA, S. P.;STAROVOJT, I. A.;FE+

  摘要：

  DOI：

文献信息

• Compounds and compositions for treating neuronal death or neurological dysfunction
  申请人：Gwag Joo Byoung

  公开号：US20070298129A1

  公开（公告）日：2007-12-27

  The present invention relates to 2-hydroxy-alkylamino-benzoic acid derivatives and to a combination of cell necrosis inhibitor and lithium, process for the preparation of the derivatives or the combination, pharmaceutical formulation containing the derivatives or the combination, and use of the derivatives or the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The derivatives and the combination of the present invention are useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration.

  本发明涉及2-羟基-烷基氨基苯甲酸衍生物及细胞坏死抑制剂和锂的组合物，以及制备该衍生物或组合物的过程，含有该衍生物或组合物的制药配方，以及通过同时或顺序给药使用该衍生物或组合物以改善神经元死亡或神经功能障碍的治疗。本发明的衍生物和组合物对于治疗神经系统疾病，如肌萎缩侧索硬化症（ALS，路易·格里格病）、脊髓性肌萎缩症、阿尔茨海默病、帕金森病、亨廷顿病、中风、创伤性脑损伤或脊髓损伤；以及治疗眼科疾病，如青光眼、糖尿病性视网膜病变或黄斑变性有用。
• COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION
  申请人：GWAG Byoung Joo

  公开号：US20120301551A1

  公开（公告）日：2012-11-29

  The present invention relates to 2-hydroxy-alkylamino-benzoic acid derivatives and to a combination of cell necrosis inhibitor and lithium, process for the preparation of the derivatives or the combination, pharmaceutical formulation containing the derivatives or the combination, and use of the derivatives or the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The derivatives and the combination of the present invention are useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration.

  本发明涉及2-羟基-烷基氨基苯甲酸衍生物以及细胞坏死抑制剂和锂的组合物，制备衍生物或组合物的方法，含有衍生物或组合物的制药配方，以及通过同时或顺序给药使用衍生物或组合物来改善神经元死亡或神经功能障碍的治疗。本发明的衍生物和组合物对于治疗神经系统疾病非常有用，例如肌萎缩性侧索硬化症（ALS，路易·格里格氏病），脊髓肌肉萎缩症，阿尔茨海默病，帕金森病，亨廷顿病，中风，创伤性脑损伤或脊髓损伤；以及治疗眼科疾病，如青光眼，糖尿病性视网膜病变或黄斑变性。
• Methods and compositions for the treatment of the skin
  申请人：SCOTIA PHARMACEUTICALS LIMITED

  公开号：EP0132126A1

  公开（公告）日：1985-01-23

  Skin regions associated with excess sebum production, eg oily regions, seborrheic dermatitis and dandruff may be treated by the topical application to such regions of a cosmetic composition containing an effective amount of a topically acceptable lithium salt.

  在与皮脂分泌过多有关的皮肤部位，如油性皮肤部位、脂溢性皮炎和头皮屑部位，局部使用含有有效量的局部可接受的锂盐的化妆品组合物，可以起到治疗作用。
• Anti-viral compositions
  申请人：SCOTIA PHARMACEUTICALS LIMITED

  公开号：EP0135312A2

  公开（公告）日：1985-03-27

  The anti-viral effectiveness of conventional anti-viral agents such as acyclovir, idoxuridine, vidarabine etc. is enhanced by formulation with a physiologically acceptable lithium salt.

  传统抗病毒药物如阿昔洛韦、伊多呋啶、维达拉宾等的抗病毒效果可通过与生理上可接受的锂盐配制而得到增强。
• Pharmaceutical compositions
  申请人：SCOTIA PHARMACEUTICALS LIMITED

  公开号：EP0234733A1

  公开（公告）日：1987-09-02

  This invention relates to the treatment of presenile or senile dementia and in particular to the treatment of Alzheimer's disease. It is proposed that such conditions may be combatted or their effects alleviated by the administration of a physiologically acceptable lithium compound and/or of an essential fatty acid or a physiologically acceptable salt thereof and there is described herein the use of lithium compounds and/or essential fatty acids or salts thereof for the manufacture of therapeutic agents for combatting such conditions.

  本发明涉及先本性或老年性痴呆症的治疗，特别是阿尔茨海默氏症的治疗，建议通过服用生理上可接受的锂化合物和/或必需脂肪酸或其生理上可接受的盐来防治此类病症或减轻其影响，本发明描述了锂化合物和/或必需脂肪酸或其盐用于制造防治此类病症的治疗剂。